A nonselective ex vivo assay was used to directly detect and quantify zidovudine (AZT)-resistant human immunodeficiency virus type 1 (IiV-1) in the blood of treated and untreated patients. In contrast to previous reports, drugresistant virus was detected in peripheral blood mononuclear cells of a few of the patients who had never received AZT. The AZT resistance of HIV-1 isolates from one untreated individual was confirmed by further susceptibility studies in vitro and by the finding of a characteristic mutation (Lys --Arg at codon 70) in the reverse transcriptase. In patients who were clinically stable while on AZT, iHV-1 titers in plasma and mononuclear cells were generally low but resistant viruses already predominated. In those individuals who were deteriorating despite AZT administration, high levels of viremia were observed, and the resistance phenotype was nearly universal. These lmdings serve to emphasize the magnitude of the AZT-resistance problem in patients on drug treatment.
The human immunodeficiency virus type 1 (HIV-1) is the etiologic agent of the acquired immune deficiency syndrome (AIDS). In 1985, zidovudine (3'-azido-3'-deoxythymidine; AZT) was found to inhibit the HIV-1 reverse transcriptase (RT) and to block viral replication in vitro at a concentration of 0.1 gM or higher (1) . A promising phase 1 study (2) led to a multicenter collaborative trial that showed that AZT decreased the number of adverse clinical events and prolonged survival in patients with AIDS or AIDS-related complex (ARC) (3) . Subsequently, additional studies have found that AZT slowed disease progression in seropositive asymptomatic persons and early ARC patients (4, 5) . AZT is one ofonly three licensed antiretroviral drugs in the United States and is now widely used.
The clinical benefit of AZT is often limited due to its adverse side effects such as gastrointestinal intolerance and hematoxicity (6) . Moreover, the emergence of AZT-resistant HIV-1 in patients on prolonged therapy has been described by Larder et al. (7) . In addition, they found that the resistance phenotype is correlated with distinct genotypic changes in the RT gene, including mutations at codons 67, 70, 215, and 219 (8) . These studies, however, were performed on HIV-1 isolates that had been propagated in transformed cell lines, a highly selective situation. Given that HIV-1 exists in each patient as a population of diverse yet related viruses (9, 10), biases introduced by in vitro selection can lead to results that poorly reflect the situation in vivo. Thus, studies on viruses cultivated in vitro can only reveal the "tip of the iceberg" of AZT resistance in vivo. We therefore attempted to detect and quantify AZT-resistant HIV-1, without the artifact of in vitro selection, in the plasma and peripheral blood mononuclear cells (PBMCs) of 24 AZT-treated and 14 untreated patients in various stages of HIV-1 infection.
METHODS
Patients. Informed consent was obtained from each of 38 HIV-1-seropositive subjects. Ten had asymptomatic infection, 8 had ARC, and 20 had AIDS. For data analysis, these study subjects were also divided into three groups as shown in Table 1 : patients who never received AZT, patients who were clinically stable while on AZT, and patients who were worsening while on AZT and were eligible for dideoxyinosine because of AZT failure. The clinical and treatment information for each of the patients is presented in Table 2 .
Quantitation of AZT Resistance in Plasma and PBMCs ex Vivo. The quantitation of AZT-resistant HIV-1 in the plasma and PBMCs of patients was performed using the end-pointdilution culture method (11) . Plasma was obtained from heparinized blood samples by centrifugation, and PBMCs were obtained by Ficoll/Hypaque density gradient centrifugation. Decreasing inocula of plasma (1000, 100, 10, 1, and 0 Al) and PBMCs (106, 10, 104, 103, 102, and 0 cells) were each cultured with 2 x 106 phytohemagglutinin-activated PBMCs from healthy blood-bank donors in 1.5 ml of RPMI 1640 medium containing 20%o (vol/vol) fetal bovine serum and interleukin 2 (10 units/ml) but no AZT. Additional aliquots of each sample were similarly titered in the presence of increased concentrations of AZT (1, 5, or 25 AtM). All cultures were washed three times with medium 24 h later. Subsequently, the cultures were maintained for 3 weeks with twice weekly medium changes, during which the appropriate concentrations of AZT were added back to the cultures. HIV-1 expression was then detected by assaying the supernatant for p24 core protein production by using a commercial immunoassay (Abbott). A culture was considered positive if the concentration of p24 exceeded 1000 pg/ml on a single determination or >200 pg/ml on two or more determinations. The lowest number of PBMCs or the smallest volume of plasma required to produce a positive culture was taken as the end point, and the titers of infectious HIV-1 were then expressed as <1, 1, 10, 100, 1000 and . 10 tTo whom reprint requests should be addressed.
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. RESULTS Fig. 1 summarizes results from 14 patients who reportedly never received AZT on detailed questioning. The lack ofAZT use was confirmed by normal mean corpuscular volumes in all patients and by the absence of detectable AZT in the serum of patients 9-11 (data not shown). Eight of these patients had detectable plasma viremia. The total HIV-1 titer in plasma ranged from <1 to 100 TCID/ml with a mean value of 17 TCID/ml. However, within the limits ofdetection ofour assay, HIV-1 with resistance to -1 AM AZT was not detected in the plasma of any of these patients. HIV-1 was recovered from the PBMCs of all 14 patients with titers from 1 to 1000 TCID per 106 cells and a mean titer of 195 was relatively low (13 TCID/ml), with 4 patients showing no detectable plasma viremia. In the 7 patients with detectable plasma viremia, resistance to 1 AiM AZT was found in 6, and resistance to .5 AiM AZT was observed in 3 patients. In one patient (patient 18), a large fraction of his cell-free virus was highly resistant to AZT. In PBMCs, HIV-1 titers were again relatively low (1-100 TCID per 106 cells; mean, 26 TCID per 106 cells). However, AZT-resistant HIV-1 was detected in 10 of 11 patients. Although they were clinically stable, resistant virus predominated in these AZT-treated patients as shown in the lower portion of Fig. 2 .
A dramatic difference is seen in patients who were worsening while on AZT as shown in Fig. 3 . All 13 patients had detectable plasma viremia with a high mean titer of 425 TCID/ml. Titers were similarly high in PBMCs, and the mean value was 917 TCID per 106 cells. Every patient had AZTresistant virus in both plasma and PBMCs. In four plasma and six PBMC cultures, most ofthe total HIV-1 burden was found to be highly AZT-resistant.
To verify the findings ofthe ex vivo assays described above, six of the HIV-1 isolates were chosen for further characterization in vitro. Three were obtained from cultures showing only AZT-sensitive viruses, and three were derived from cultures containing AZT-resistant viruses. As shown in Fig. 4 , HIV-1 isolates from the plasma ofpatient 4, PBMCs ofpatient 5, and plasma ofpatient 10 exhibited sensitivity to AZT in vitro with 90%o inhibitory doses (ID0) of<0.2 AiM. These results are consistent with those generated in the ex vivo assays (Fig. 1) . By contrast, viral isolates defined as AZT-resistant in the ex vivo assay (from PBMCs of patients 10, 11, and 25) demonstrated moderate to marked resistance to AZT in vitro (Fig. 4) . Thus, the findings from these in vitro assays appear to validate the results obtained in the ex vivo assays. In particular, the resistance phenotype of HIV-1 isolates (PBMCs of patients 10 and 11) from patients who never received AZT has also been confirmed by the in vitro assay.
To define genetic changes responsible for AZT resistance in one untreated patient, the nucleotide sequences of RT genes from one AZT-sensitive plasma virus and one AZT-resistant PBMC virus from patient 10 were determined (Fig. 5) . Both RTgenes show afull-length open reading frame. The RT ofthe AZT-resistant clone showed three amino acid substitutions in the polymerase domain (codons 1-266) when compared with that of the AZT-sensitive clone, including the Lys --Arg mutation at codon 70 shown to be associated with AZT resistance in treated patients (8) . The other two substitutions are in positions where there is significant variability among sensitive HIV-1 isolates (18) and, therefore, are less likely to be involved in drug resistance. Six amino acid differences were found in the tether domain (codons 266-347), and three were noted in the RNase H domain (codons 348-559) (12) . These changes, however, are unlikely to affect AZT sensitivity.
When the data from Figs. 1-3 are summarized according to AZT use and nonuse, patients who never received AZT have only sensitive HIV-1 in plasma, although resistant virus can be detected in the PBMCs of many. In contrast, the resistant phenotype is nearly universal in patients treated with AZT.
DISCUSSION
We have found that AZT-resistant HIV-1 can be detected in the PBMCs of infected persons who have never received the drug (Fig. 1) . That the resistant virus is not found in the plasma of these individuals suggests that the AZT-resistant HIV-1 is largely latent within their PBMCs, although it is possible that resistant viruses are difficult to detect in these cases due to the low levels of viremia. Of the four patients who had highly resistant virus, three (patients 9-11) contracted HIV-1 in the pre-AZT era. In contrast, one (patient 7) is a recent seroconvertor, and it is possible that he acquired the AZT-resistant HIV-1 from a contact who received the drug. Given that HIV-1 exists in vivo as a population of diverse yet related viruses (9, 10), we believe that resistance develops de novo, perhaps due to the error-prone reverse transcription step. Initially, the fraction of drug-resistant HIV-1 is probably small. As viral replication increases with disease progression (11) , the chance of having AZT-resistant virus also increases. However, if treatment with AZT is started, the resistant population will then have a growth advantage and will thus proliferate to become the dominant population.
Our finding of AZT-resistant HIV-1 in untreated patients is in distinct contrast to published reports from several groups (7, 8, 11, 13-16 ), although acyclovir-resistant herpes simplex virus has been described in untreated patients (17 that were scored as resistant in the ex vivo assay were tested for AZT sensitivity in vitro, the same phenotype was found (Fig. 4) . Furthermore, we have shown in patient 10 that the AZT resistance detected in the ex vivo assay is associated with one of the genotypic changes characteristic of drug-resistant isolates from treated patients. We thus believe that the ex vivo approach is valid and provides information that more accurately reflects the situation in vivo.
AZT-treated patients who are clinically stable have relatively low HIV-1 titers in plasma and PBMCs, perhaps reflecting the in vivo beneficial effect of the drug (Fig. 2) . However, the resistance phenotype already predominates in these patients. It is possible that, as the AZT-resistant HIV-1 proliferates, the situation depicted in Fig. 3 high levels, and the resistant phenotype is almost universal. The data contained in Fig. 3 suggest, but do not prove, that AZT-resistant HIV-1 is pathogenic and is responsible for drug failure and disease progression.
Studies have suggested that patients early in the course of HIV-1 infection should be started on AZT because of shortterm benefits (4, 5) . However, the overall recommendation of early treatment with AZT should take into consideration the magnitude of the resistance problem as illustrated by our quantitative results. It is possible that the reported short-term benefits may eventually be offset by the earlier development of drug-resistant viruses and that with widespread use of AZT, the modest beneficial effect of the drug may diminish in time. This concern emphasizes the urgent need to quickly develop other anti-HIV drugs for clinical use.
